FWBI Stock Quote Price and Forecast | CNN

FWBI

First Wave BioPharma, Inc.

Key terms

First Wave Biopharma, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of non-systemic therapies for the treatment of gastrointestinal diseases. The firm is involved in a therapeutic development pipeline populated with multiple clinical stage programs built around its proprietary technologies, such as Niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. Its programs include FW-UP, FW-UC, FW-CD, FW-COV, FW-ICI-AC, MS1819, COVID-19 GI infections, and FW-EPI. The company was founded on January 30, 2014 and is headquartered in Boca Raton, FL.

Sector

Industry

Employees

Founded

Website

Key stock statistics

1-day range

52-week range

Market cap

P/E ratio

Next earnings date

Dividend yield

Ex-dividend date

Dividend pay date

Key terms

Smart score

Apr 11 4:46pm ET Meet First Wave BioPharma: Exclusive interview with CEO James Sapirstein by TipRanks Apr 11 4:45pm ET First Wave BioPharma ‘way undervalued,’ CEO Sapirstein says by TipRanks Apr 11 4:45pm ET First Wave CEO says in process of capital raise, sees share price going up by TipRanks Apr 11 4:45pm ET First Wave CEO says strategic partner news should be major boost for stock by TipRanks Mar 31 2:02am ET First Wave Bio Inc. Grapples with Uncertainty in Pending Niclosamide Deal by TipRanks Mar 25 6:09am ET First Wave BioPharma reinstated with a Neutral at H.C. Wainwright by TipRanks Mar 18 7:03am ET First Wave BioPharma announces acceptance of two abstracts on celiac disease by TipRanks Mar 15 8:27am ET First Wave BioPharma price target lowered to $36 from $40 at Roth MKM by TipRanks Mar 14 6:22am ET First Wave Bio Merges with ImmunogenX, Eyes Celiac Breakthrough by TipRanks Mar 05 5:42pm ET First Wave Bio Launches Equity Offering for Corporate Funding by TipRanks Mar 04 8:07am ET First Wave to sell 525,625 shares at $7.61 in registered direct offering by TipRanks

No recent news articles are available for FWBI

No recent press releases are available for FWBI

1-year income & revenue

Key terms

analyst rating

buy
hold
sell

1-year stock price forecast

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Tim Wren, chief commercial officer for BSI Group, right, presents Kristalina Georgieva, chief executive officer of the World Bank Group, second right, with ISO 20121 certification for sustainable event management at an event during the spring meetings of the International Monetary Fund (IMF) and World Bank in Washington, DC, US, on Monday, April 15, 2024. The IMF and World Bank spring meetings in Washington are expected to draw thousands of delegates, observers and journalists from the fund's 190 member countries. Photographer: Samuel Corum/Bloomberg via Getty Images

Samuel Corum/Bloomberg/Getty Images

Geopolitical strife is roiling Wall Street. Here’s what investors are watching

Donald Trump might no longer own a majority of TMTG after a new public share offering.

Joe Raedle/Getty Images

Trump stock tanks after announcing massive share sale

1040 US Individual Income Tax Return Form

Nora Carol Photography/Moment RF/Getty Images

Three ways investors can minimize their tax payments

People walk past the New York Stock Exchange (NYSE) on April 10, 2024 in New York City.

Spencer Platt/Getty Images

Dow closes nearly 500 points lower on fears of potential Iranian attack on Israel